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Summary One hundred and forty-eight patients with Hodgkin's disease (HD) were stratified into 4 groups
according to atopic status. Group 1 had a personal history of atopy and Group 2 a family history of atopy. In
Groups 3 and 4 there was no history of atopy but high serum IgE levels (Group 3) and normal IgE levels
(Group 4). Comparison of the survival of these groups by the logrank method showed a significant trend
(P= <0.0001) where survival was ranked Group 1>2>3>4.
Known prognostic factors in HD-age, sex, stage, symptoms and histology-had to be taken into account,
since their distribution differed between the atopic groups. In Group I there was more stage IA and IIA
disease and less "B" symptoms, in Group 3 more nodular sclerosis histology and more "B" symptoms and in
Group 4 more lymphocyte-depleted histology and a higher mean age than expected from their distribution in
the combined groups. Adjustment to allow for the variation in each of the other prognostic factors and for a
combination of age, symptoms and histology still showed a significant trend of survival on the basis of atopic
status. The increased survival of atopic patients suggests that atopic mechanisms or the genetic basis to atopy
has a protective effect in HD either directly or by interaction with treatment.
Atopy was a term introduced by Coca & Cooke
(1923) to describe the syndrome of common allergic
diseases-hay fever, asthma, atopic eczema and
urticaria-which had a genetic basis. The
conundrum exists to this day as to why this
complex immune system, involving B cells
producing predominantly the IgE class of
antibodies and a regulatory T cell system,
basophils, mast cells and eosinophils, should be
maintained when it apparently turns harmless
environmental antigens into allergens detrimental to
the health of the host. Teleologically, the most
plausible explanation is that this system evolved as
a protection against helminthic infestation,
although the role that antibodies of IgE class play
in helminthic immunity has not clearly been
established (Ogilvie & Jones, 1973). In developed
countries where public health measures have all but
eradicated the major helminthic parasites it is
possible that this system has become redundant and
its expression in hyper-reactive individuals is atopic
disease.
Another role has been suggested for IgE in
protective immunity against cancer. Early studies
purported to show that the incidence of atopy was
decreased in cancer patients (Fisherman, 1960;
Mackay, 1966) but subsequent large controlled
studies were unable to verify the earlier claims
(McKee et al., 1967; Shapiro et al., 1971) and the
consensus of opinion now is that the presence of
atopy does not protect against oncogenesis (for
review, see Rosenbaum & Dwyer, 1977). However
none of these studies examined how atopic cancer
patients fared compared to their non-atopic
counterparts. The present study examines the effect
of pre-existing atopy on the survival of patients
with Hodgkin's disease (HD) as well as other
parameters of disease expression. From the stand-
point of allergic disease, HD is a particularly apt
example of malignancy because like helminthic
parasites it is associated with raised levels of serum
IgE (Waldman et al., 1974; Amlot & Green, 1978)
and eosinophilia. The reported frequency of atopy
in HD is normal (Amlot & Green, 1978; Dworin et
al., 1955; McCormick et al., 1971) which suggests
that, as with other malignant tumours, it does not
protect atopic subjects from the development of
HD. However, it was observed in this study that
survival of atopic patients was significantly
improved compared with those who were non-
atopic.
Patients and methods
Patients
One hundred and forty-eight patients with
Hodgkin's disease (HD) were assessed at the time
of their diagnosis and prior to treatment. One
() The Macmillan Press Ltd., 1983
Correspondence: P.L. Amlot
Received 25 March 1983; accepted 25 May 1983.210 P.L. AMLOT et al.
hundred and twenty-seven patients were seen at
Guy's Hospital between September 1972 and June
1979, while the remaining 21 were seen at the
London Hospital between April 1974 and April
1977. Follow-up of survival and disease status was
monitored in December 1979.
Staging of the patients accorded with the Ann
Arbor system (Carbone et al., 1971). Clinical
staging routinely included lymphography and bone
marrow trephine biopsy. Selective staging
laparotomy and splenectomy were carried out in 74
cases. Prior unequivocal "B" symptoms (59
patients), contraindication to operation (8 patients)
and clinical stage IA disease with lymphocyte
predominance or nodular sclerosis (7 patients) were
reasons for not performing staging laparotomies in
the remainder.
Histology was classified according to Lukes &
Butler (1966) and grouped as lymphocyte
predominance (LP), nodular sclerosis (NS), mixed
cellularity (MC) or lymphocyte depletion (LD).
Atopic symptoms
Past or present personal histories of hay fever,
perennial rhinitis, asthma, atopic eczema or
urticaria and similar family histories were elicited
from each patient. Questionnaires were sent to each
member of the patient's direct family requesting the
same information and were answered by all except
11 families. Doubtful symptoms, drug allergies,
contact dermatitis and atopy evidently arising from
the unaffected spouse's side of the family were
disregarded. Family history extended to
grandparents, parents, siblings, children, uncles,
aunts and first cousins.
Patients were stratified on atopic status according
to their atopic history and pre-treatment serum IgE
level. Group 1 were those with a personal history
of atopy; Group 2 had a family history but no
personal history of atopy; Groups 3 and 4 had
neither personal nor family history of atopy but
had high and normal levels of serum IgE
respectively.
Measurement ofIgE
This was performed on a pre-treatment serum
sample from all patients using a double antibody
radio-immuno assay (Amlot & Green, 1978).
Normal IgE levels were determined from 275
healthy, non-atopic subjects whose geometric mean
IgE was 15IUml-1 (loglo1.8+0.51). The upper
limit for normal IgE levels was set at 159IUml-1
(antilog log, 01.18+2 x 0.51).
Prick tests were performed on the majority of
patients using a battery of common inhalant
allergens described recently elsewhere (Amlot &
Slaney, 1981).
Treatment
The treatment policy was the same for all patients.
Primary treatment for stage IA and IIA was by
"mantle" or "inverted" Y fields (Kaplan &
Rosenberg, 1975) to a minimum of 3,500cGy over
4 weeks. Stage IIIA was treated by total nodal
irradiation to the same dosage over 10 weeks.
Patients with stages IB, IIB, IIIB, IVA and IVB
were treated by combination chemotherapy
predominantly with MOPP (De Vita et al., 1970)
and in the remainder by the MVPP variation
(Nicholson et al., 1970).
Patient survival
Time of survival was calculated from diagnosis.
Complete remission (CR) was the clinical
disappearance of all disease induced by the primary
treatment and which persisted for at least 3 months
after the end of treatment. Patients who attained
CR and subsequently relapsed or who only
achieved partial or no-response but who had not
died, were designated poor remission or relapse.
Many such patients attained CR with further
therapy.
Statistical analysis
Life tables for the different groups were obtained
and compared by the Logrank test (Peto et al.,
1977) using the London School of Hygiene and
Tropical Medicine's version of the Surv-C
programme (Peto et al., 1977) and run at the
University of London Computer Centre. Allowance
was made for prognostic factors which were shown
to affect survival. Statistical analysis elsewhere was
by x2 for contingency tables.
Results
The characteristics of the groups 1-4 in respect of
atopy are shown in Table I. In Group 1 the
complete atopic diathesis was seen with atopic
symptoms, positive prick tests and elevated IgE
levels, while Group 2 shared with it an increased
frequency of positive prick tests and moderately
raised IgE levels having antibody activity for
common inhalant allergens (shown previously by
RAST) (Amlot & Slaney, 1981). Group 3 had the
highest IgE levels but in this group the IgE rarely
had demonstrable allergen specific antibody,
(Amlot & Slaney, 1981). Group 4 showed no
evidence of atopy apart from a low incidence ofATOPY AND SURVIVAL IN HD 211
Table I Details of atopic strata among patients with Hodgkin's disease
Atopic history Prick test responses
No. tested Geometric mean
Atopic %+ve %+ve IgE level in
group Personal Family No. in group >5mm 3-Smm IUml-
1 + + or - 29/29 69 24 186
2 - + 23/26 26 43 54
3 - - 24/31 4 21 794
4 - - 40/62 5 15 18
positive prick tests. This stratification graded
patients with unequivocal atopy through to those
with least evidence of atopy.
Prognosticfactors affecting survival in HD
These are shown in Table II. The known prognostic
factors can be divided into 2 types. First, those like
age and sex which precede and are separate from
the disease process but which somehow modify the
disease. Second, those factors like stage, symptoms
and histology which are expressions of the severity
of the disease. The reasons for the degree of
severity in an individual patient are unknown.
Table II Statistical analysis of prognostic factors for
survival in Hodgkin's disease
Relative death
Prognosticfactor rate (OIE) x2for trend P-value
Stage I 0.33
II 0.44
III 1.22 8.67 0.003
IV 1.56
SymptomsA 0.54 14.12 0.0002
B 1.83
Histology LP 0.19
NS 0.66 15.63 0.0001
MC 0.9
LD 2.7
Age <40yr. 0.5 16.77 <0.0001
240yr. 1.9
Sex Male 1.17 1.28 0.3
Female 0.76
Atopic
Status Group 1 0.22
Group 2 0.38
Group 3 0.85 18.24 <0.0001
Group 4 1.89
The widely described effect of stage, symptoms
and histology on prognosis was again confirmed by
this study. Less often reported is the influence of
age on survival (Axtell et al., 1972) which has
disclosed a markedly decreased survival in older
patients. The age analysis shown in Table II divided
patients into those above and below 40 years of age
because this corresponded with the trough between
the 2 peaks of the bimodal age distribution in HD.
However, a number of age strata were analysed and
all showed an adverse prognosis in age groups >40
years, and the prognosis was worse the older the
age grouping. The relative death rates for the 2 age
groups were little changed and still significant after
stratification for stage (P=0.0001), symptoms
(P=0.0001) and histology (P=0.0006).
Females had a slightly improved survival
compared with males but this was not significant.
The novel discovery in this study was the
significant effect of atopic stratification related to
survival in HD (Figure 1). When survival of these
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Figure 1 Survival in HD based on atopic
stratification, No. of patients alive and under
observation at diagnosis and 12 monthly therafter.
Group 1: 29, 24, 20, 15, 13, 8 & 7. Group 2: 26, 23,
19, 11, 8, 4 & 2. Group 3: 31, 21, 17, 12, 11, 5 & 1.
Group 4: 62, 40, 25, 21, 16, 9 & 4.212 P.L. AMLOT et al.
groups was analysed (Table II) there was a highly
significant trend whereby survival was ranked
Group 1>2>3>4.
Distribution of the other prognostic factors among
the atopic strata
The difference in survival between Groups 1-4
could be due to less severe disease in Groups 1 and
2 (Stage I or II, A symptom status and LP or NS
histology) with correspondingly more severe disease
in Groups 3 and 4 (Stage III or IV, B symptom
status and MC or LD histology). There was, in
fact, significant heterogeneity among the groups
both as far as stage and symptoms (Table III) and
histology (Table IV) were concerned, but not in the
clear cut manner outlined above. In Group 1 there
was an increased proportion of patients with Stage
IA and IIA disease. There was a concomitant
decrease in patients with Stages IB-IVB. The
reverse was found in Group 3. As there were only 4
patients in Stage IB and IIB these stages were
grouped with IIIB and IVB. The heterogeneity of
histology among the atopic strata is shown in Table
IV. The high proportion of patients in Group 3
with NS histology was expected from a previous
study (Amlot & Green, 1978). Group 4 had an
increase of LD histology.
Group 4 also had an older mean age than the
other 3 atopic groups. The mean age (and age
range) were as follows: Group 1, 35.8y. (15-73);
Group 2, 31.8y (13-59); Group 3, 34.4y (16-66);
Group 4, 44.8y (17-81).
Table m Distribution of stage and symptoms among the
atopic groups
Stage and symptom status
Atopic
group IA, IIA IIIA, IVA IB-IVB
1 19 7 3
(65.5%) (24.1%) (10.4%)
2 7 10 9
(26.9%) (38.5%) (34.6%)
3 3 7 21
(9.7%) (22.6%) (67.7%)
4 19 14 29
(30.6%) (22.6%) (46.8%)
ALL 48 38 62
(32.4%) (25.7%) (41.9%)
2= 29.59 (P=0.00005)
Table IV Distribution of histology among the atopic
groups
Histology
Atopic
group LP NS MC LD
1 6 8 10 5
(20.7%) (27.6%) (34.5%) (17.2%)
2 1 7 14 4
(3.9%) (26.9%) (53.8%) (15.4%)
3 3 17 9 2
(9.7%) (54.8%) (29%) (6.5%)
4 8 10 27 17
(12.9%) (16.1%) (43.6%) (27.4%)
ALL 18 42 60 28
(12.2%) (28.4%) (40.5%) (18.9%)
2=22.03 (P=0.001)
Analysis of atopic strata allowing for other
prognosticfactors
The atopic groups differed as regards age, stage,
symptoms and histology and since the relative
death rates varied with each of these prognostic
factors (Table II) their contribution to the effect of
atopy on survival had to be assessed. Allowance for
each of these prognostic factors and the adjusted
relative death rates are shown in Table V. The
trend for the atopic groups remains highly
significant. However the effect seen may still have
been due to a combination of prognostic factors so
the atopic groups had to be compared after
retrospective stratification with respect to more
than one of these factors using the logrank method.
The combination of factors chosen was age,
symptoms and histology as each showed an effect
Table V Adjusted relative death rates allowing for age
(<40y; 240y), stage symptoms and histology
individually.
Adjusted relative death rates (O/E)
allowingfor:
Atopic strata Age Stage Symptoms Histology
Group 1 0.2 0.31 0.34 0.25
Group 2 0.52 0.38 0.38 0.33
Group 3 1.01 0.68 0.62 1.09
Group 4 1.61 1.84 1.86 1.7
X2 for trend= 13.87 15.01 14.96 16.2
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upon prognosis independent of the others. Age, as
mentioned above, was an important factor even
after stratification for each of the other prognostic
factors individually. Hence, age must be allowed for
when comparing the atopic groups. However, with
stage the relative death rates did not vary
significantly after stratification for symptoms
whereas the death rates varied significantly between
those with A (O/E=0.65) and B (O/E= 1.40)
symptoms after stratification for stage (P=0.02).
Thus if allowance is made for the effect symptoms
have on prognosis there is no need to make
allowance for the effect of stage as well. Symptoms
were an important factor after allowance for age
(P=0.0002) and histology (0.01). Histology was
important after allowance for symptoms (P=0.002)
and age (P=0.001).
The atopic groups were compared after
stratification with respect to age (<40y, .40y),
symptoms and histology (Table VI). There was still
a significant trend (P=0.004) in the adjusted
relative death rates from 0.37 in Group 1 to 1.36 in
Group 4. Clearly the patients of Group 4 differed
from those of the other 3 and those in groups 1
and 2 were very similar both in their relative death
rates (Tables V and VI) and in having a history of
atopic symptoms either in themselves or in their
families. Group 3 patients had very high IgE levels
but no atopy and their relative death rate was
closer to those of Groups 1 and 2 and it could be
shown that the relative death rates for Groups 1, 2
and 3 did not differ significantly (P=0.4). On the
other hand Group 4 had a significantly worse
prognosis than groups 1, 2 and 3 combined after
stratification for age symptoms and histology
(P=0.03).
Patients .60y had the worst survival and
group 4 had a mu'ch higher percentage of these
older patients than the other groups. The
stratification for age in the previous analysis was
for those <40y or .40y. In view of the number
Table VI Adjusted relative death rates after retrospective
stratification for age (<40y, .40y), symptoms and
histology.
Atopic Adjusted relative death rates (OIE)
group All ages Age<60yr.
2 0.54}0.45 } 0.60
3 0.84 0.74
4 1.36 1.39
x2 for trend 8.43 4.94
P 0.004 0.03
of subgroups already in the analysis and that the
atopic groups 1, 2 and 3 had 3 or less aged 60 or
over, it was undesirable to repeat the previous
analysis with the .40y group split into 40-59y
and 60y. However the analysis was repeated
excluding those >60y. The relative death rates
were very similar to those of the preceeding
analysis and are shown in Table VI.
Cause ofdeath
In the majority of deaths the primary cause was
HD and there was no clear difference in cause of
death between the atopic strata. Complicated
deaths from other causes were: in Group 1, one
patient with paraplegia had renal infection and
recurrent septicaemia and another had a
hypereosinophilic state (50,000,ul-1) followed by
acute tubular necrosis subsequent to laparotomy
while both were in relapse. In Group 2 one patient
died of acute myeloid leukaemia while in CR. In
Group 3 three patients died in CR, one from
myocardial infarction, and the other two from
carcinoma of the lung. In Group 4 one patient died
from peritonitis while in CR, one from
complications of paraplegia while in relapse, one
from multiple system failure with minimal hepatic
HD and one patient who died at home while in
relapse.
Excluding the patients above re-analysis of
survival still showed a highly significant trend
(P<0.0001) for atopic strata.
Discussion
Atopic status was stratified in this study because it
is known to be a multifactorial disease often having
a late onset. Thus apart from those patients who
had clearly suffered from atopic symptoms prior to
developing HD (Group 1) there was a group of
patients with a genetic predisposition to atopy
many of whom had evidence of atopic
hypersensitivity without having developed atopic
symptoms (Group 2). The peak age for subjects
developing hay fever lies, like HD, in the third
decade and its development is more prevalent in
those with a family history of atopy. Even in those
Groups 3 and 4 where atopy was not evident there
were occasional individuals with positive prick tests
and who therefore risked development of atopic
symptoms at a later date. The relationship between
prolonged survival and positive prick tests will be
dealt with in a subsequent paper. Comparison of
survival, prompted initially by the observation that
atopic patients (Group 1) rarely had "B"
symptoms, led to the discovery that this atopic
c214 P.L. AMLOT et al.
stratification was associated with survival whereby
atopy had a favourable effect even after
stratification for age, symptoms and histology.
There is a difference between prognostic factors
such as age, sex and atopy coming before the onset
of HD and those such as stage, symptoms and
histology which are established with its diagnosis.
The latter group are clearly the most reliable in
predicting prognosis for HD but it leaves
unanswered the question as to why in an individual
patient HD presents with a lesser or greater stage
and severity. Length of history is not a reliable
guide, even assuming that the disease progresses at
a uniform rate in all patients. The site at which
disease starts may be a more important indicator
since abdominal lymphadenopathy is frequently
associated with "B" symptoms and evidently can
progress much further before being detected than in
patients presenting with peripheral
lymphadenopathy in the neck. Histological
classification provides suggestive evidence that
lymphocytes and "benign" histiocytes represent a
host response to Reed-Sternberg (RS) and Hodgkin's
cells ("malignant histiocytes") and thus are a key
factor in restricting the spread of HD (Lukes &
Butler, 1966; Coppleson et al., 1973). Although
there is clear evidence that the higher the ratio of
lymphocytes and "benign" histiocytes to Hodgkin's
cells the better the prognosis, no direct evidence of
lymphocyte cytotoxicity towards Hodgkin's or RS
cells has been forthcoming. This work has been
hampered by the difficulty in isolating and
establishing tissue culture lines of Hodgkin's cells
against which lymphocytes could be tested.
Interest in factors preceding the development of
HD yet affecting its final outcome lies in the
possibility of identifying host resistance mechanisms
for HD. Age of onset is clearly an important factor.
Although the effect of age is independent of the
other prognostic variables, among 19 in the older
age group (.60y) there was a 95% frequency of
MC or LD histology and a 63% frequency of Stage
IIIB or IVB. These findings were similar to the
same age group reported by Lokich et al., (1974) in
which 83% of 47 patients had MC or LD histology
and 81% had stage III or IV disease. Median
survival of 5 months was very poor and may partly
have been explained by the palliative treatment
given in some cases. We attempted to give full
treatment in this group and still only achieved a
median survival of 10 months for the 12 who had
died during the study period. Older patients
tolerated full dosage of treatment poorly and
prolonged bouts of myelosuppression with its
associated complications probably played a
significant part in the poor results. Evidently age
per se is not a manipulable resistance factor and the
lack of resistance to HD in the .60y old patients
does not define the causative factors.
The recognition of atopy as having a favourable
effect upon survival in HD raises interest in the
possible mechanism by which it acts. Atopy is a
complex disorder involving immunological
mechanisms of immediate hypersensitivity as well as
non-immunological ones such as increased
sensitivity to a adrenergic stimuli and decreased f
adrenergic receptors. However, it is the vigorous
production of IgE antibodies in response to low
doses of antigen that is the most clearly defined
feature. Consequently the protective mechanism
most readily suggested is the production of anti-
tumour IgE antibody and limitation of disease
spread as a result of tissue sensitisation and the
action of accessory effector cells. It is known that
rodent melanoma and fibrosarcoma induce specific
reaginic responses (Bartholomaeus & Kaest, 1972;
Broom & Alexander, 1975). Furthermore there
have been suggestions of both basophil (Dvorak et
al., 1973) and mast cell (Likhite, 1974) involvement
in tumour resistance. Against this we have been
unable to demonstrate IgE antibody bound to
Hodgkin's cells in fresh biopsies or subsequent
binding using high IgE serum (unpublished results)
but the method used (immunofluorescence) may not
have been sensitive enough. Also reports of wheal
and flare responses to tumour extracts are rare
(Grace & Kondo, 1958) in contrast to those
frequently reported in helminthic disease.
A less obvious means by which atopy may
influence tumour growth is based on the cellular
mechanisms underlying control IgE antibody
production. It is not surprising that the potentially
damaging IgE antibody is under strong T
lymphocyte suppressor control which is presumably
abnormal in atopic subjects. Helminthic parasites
can stimulate IgE synthesis with loss of suppressor
control during infestation. It was found that
tumour growth is inhibited in rodents infested with
helminths (Keller et al., 1971). In these experiments
no reaginic antitumour antibody was demonstrated
but surprisingly the tumour inhibition was
abolished when rodents were treated with anti-
lymphocyte antiserum. At the time it was difficult
to interpret these results but development of
specific antisera for rodent supressor cells has
demonstrated that tumour growth may be inhibited
when suppressor cells are eradicated (Perry et al.,
1978; Tilkin et al., 1981). These studies suggest that
in normal individuals the powerful suppressor
control of IgE synthesis may be linked to
suppressor control of cellular responses towards
weak antigenic systems such as tumour antigens.
Abrogation of suppressor control may
paradoxically benefit the tumour bearing host. ItATOPY AND SURVIVAL IN HD 215
may also be relevant that in both these
experimental systems tumour growth was inhibited
but not abolished which is similar to the effect of
atopy in HD.
HD is a variable disease that runs a variable
course. Assuming that it is a single disease entity
and that its different manifestations and
progression are reflections of a "host-tumour
interaction" then factors that influence it are of
interest for their positive and negative effects on
prognosis. This study shows that atopy is a factor
that precedes the development of HD and
correlates favourably with its outcome.
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